Aldevron has added GMP gene synthesis to its portfolio of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company said the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.   Neoantigens are proteins generated by tumor-specific mutations that have significant potential in treating cancer. The T cell...